ClinicalTrials.gg
CompletedNCT03497689Updated Aug 7, 2023Results posted

EXPEDITE: A Study of Remodulin Induction Followed by Orenitram Optimization to Treat Pulmonary Arterial Hypertension

A Phase 4 interventional study of Intravenous/Subcutaneous Treprostinil; Oral Treprostinil in Pulmonary Arterial Hypertension, sponsored by United Therapeutics. Completed at 11 sites in United States. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-08-07.

Sponsored by United Therapeutics · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
36
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
18th of 44
36 · median 32
Started
2019
with 4 others
Phase 4
14 of 44
1 open now
Registered
34th of 44
by date
Lead sponsor
32 of 44
United Therapeutics

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 18th largest by enrollment, is one of 5 that started in 2019, is one of 14 in phase 4, and was the 34th registered.

Pulmonary Arterial Hypertension

700 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

This was a multicenter, open-label study to evaluate the dose of Orenitram® (treprostinil) Extended Release Tablets achieved at 16 weeks after a short-term course of Remodulin® (treprostinil) Injection in subjects with pulmonary arterial hypertension (PAH).

Read the detailed description

Subjects were initiated on subcutaneous (SC) or intravenous (IV) treprostinil and titrated to a dose that improved the symptoms of PAH while minimizing excessive pharmacologic effects. After achieving a minimum SC/IV treprostinil dose of 20 ng/kg/min, subjects began a transition to oral treprostinil at the Transition Visit, which occurred at the Week 2, 4, or 8 study visit. After the Transition Visit, oral treprostinil titration continued through Week 16 to reach the maximum tolerated dose (MTD).

03

Conditions studied

  • Pulmonary Arterial Hypertension

Keywords

  • Pulmonary hypertension
  • Treprostinil
  • Pulmonary arterial hypertension
  • Remodulin
  • Orenitram
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects who voluntary gave written to participate in study.
  2. Males and female subjects aged 18 to 75 years at Screening (date the subject provided written informed consent to participate in study).
  3. Subjects with a diagnosis of World Health Organization (WHO) Group 1 pulmonary hypertension (PH): symptomatic idiopathic or heritable PAH; or PAH associated with connective tissue disease, (HIV) infection, repaired congenital systemic-to-pulmonary shunt (at least 1 year since repair with respect to the date of providing informed consent), or appetite suppressant/toxin use.
  4. Subjects with WHO functional class (FC) II or III symptoms at Baseline.
  5. Subjects with 6MWD >250 m at Baseline.
  6. Subjects who were either not receiving PAH-targeted therapy or were currently being treated with 1 or 2 oral FDA-approved PAH therapies consisting of an endothelin receptor antagonist (ERA) and/or either a phosphodiesterase type-5 inhibitor (PDE5-I) or a soluble guanylate cyclase (sGC) stimulator for ≥45 days, and on a stable dose for ≥30 days prior to the Baseline Visit.
  7. Subjects on stable doses of other medical therapies for at least 10 days prior to the Baseline Visit, with no dose adjustments, additions, or discontinuations, with the exception of discontinuation or dose changes of anticoagulants and/or diuretics. Subjects could not have recent changes to non-pharmacologic interventions, such as exercise, diet plans, pulmonary rehabilitation, or sleep apnea treatment, for at least 10 days prior to Baseline Visit.
  8. Subjects with historical right heart catheterization (RHC) results consistent with WHO Group 1 PH, as demonstrated by pulmonary artery pressure mean of ≥25 mmHg, a pulmonary artery wedge pressure (PAWP) or left ventricular (LV) end-diastolic pressure ≤15 mmHg (if a PAWP measurement was not available) and a pulmonary vascular resistance (PVR) >3 Wood units, in the absence of unrepaired congenital heart disease (other than patent foramen ovale).
  9. Subject underwent an RHC within 180 days of Baseline and had a cardiac index ≥2.0 L/min/m² with no changes in their PAH medication regimen (ie, both dosing and drug) since the RHC.
  10. Subjects with most recent historical echocardiogram (ECHO) demonstrating clinically normal left systolic and diastolic ventricular function and absence of any left-sided heart disease. Subjects with clinically insignificant LV diastolic dysfunction due to the effects of right ventricular (RV) overload (RV hypertrophy and/or RV dilation) were eligible.
  11. Subjects who agreed to follow the specified precautions to avoid pregnancy as follows:

    1. For female subjects of , a negative urine pregnancy test was required at Screening and Baseline prior to initiating study drug. Female subjects of childbearing potential must have followed 1 of the following approaches: i. practice actual abstinence from intercourse, ii. had a partner with a vasectomy, iii. had an intrauterine device, or iv. must have used 2 different forms of highly effective for the duration of the study, and for at least 48 hours after discontinuing study drug. Medically acceptable forms of effective contraception included approved hormonal contraceptives (such as birth control pills) or barrier methods (such as a condom or diaphragm).
    2. Male subjects with a partner of childbearing potential must have used a condom during intercourse for the duration of the study, and for 48 hours after discontinuing study drug.
  12. HIV-positive subjects must have had a of at least 200 cells/mm\^3 within 30 days of Screening and been receiving current standard-of-care anti-retroviral or other effective medication for the treatment of HIV, with no changes for at least 8 weeks prior to enrollment.
  13. Subjects who, in the opinion of the Investigator, were capable of communicating effectively with study personnel and were considered reliable, willing, and likely to be cooperative with protocol requirements and attend all required study visits.
  14. Subjects who had the capability to answer surveys and questionnaires written in English.

Exclusion criteria

Exclusion Criteria:

  1. Female subjects who were pregnant, lactating, or planning to become pregnant during the study.
  2. Subjects with a current diagnosis of uncontrolled sleep apnea, as defined by their physician.
  3. Subjects with renal insufficiency, as defined by requiring dialysis or an estimated of \<30 mL/min, as calculated by the Cockcroft-Gault equation.
  4. Subjects with liver dysfunction defined as elevated liver function tests ( or aspartate aminotransferase) ≥3 times the at Screening, or subjects with Class B or C hepatic disease.
  5. Subjects with anemia, as defined by Screening \<9 g/dL.
  6. Subjects with an active infection or condition that interfered with interpretation of study assessments.
  7. Subjects with a history of ischemic heart disease (defined as subjects who required anti-anginal therapy within 6 months of Screening or who had experienced a documented myocardial infarction within 6 months of Screening) or a history of left-sided myocardial dysfunction, as evidenced by a PAWP >15 mmHg or LV \<50%.
  8. Subjects with uncontrolled systemic hypertension, as evidenced by systolic blood pressure >160 mmHg or diastolic blood pressure >100 mmHg at Baseline.
  9. Subjects with severe hypotension, as evidenced by systolic blood pressure \<90 mmHg or diastolic blood pressure \<50 mmHg at Baseline.
  10. If a lung assessment was completed as per standard of care, any subject with 1 or more of the following signs of documented relevant lung disease within 180 days of Baseline: total lung capacity \<60% of predicted or \<55% of predicted normal.
  11. Subjects with chronic musculoskeletal disorder or any other disease that limited ambulation, or who were connected to a machine that was not portable.
  12. Subjects with a history of alcohol abuse or illicit drug abuse within 12 months of Baseline which, in the Investigator's opinion, made the subject inappropriate for enrollment in a clinical study.
  13. Subjects with any other concomitant disease with of \<12 months from Baseline.
  14. Subjects with an unstable psychiatric condition or those not capable of understanding the objectives, nature, or consequences of the study, or who have any condition which, in the Investigator's opinion, constituted an unacceptable risk to the subject's safety.
  15. Subjects who were currently receiving an drug, had an investigational device in place, or who had participated in an investigational drug or device study within 180 days prior to Baseline. Participation in an observational study within 180 days prior to Baseline did not disqualify a subject from enrolling.
  16. Subjects who had received a prostacyclin-class therapy within 28 days of Baseline.
  17. Subjects who had a Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL) 2.0 Risk Score of ≥10.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Intravenous/Subcutaneous Treprostinil; Oral Treprostinil

    Subjects began Remodulin at 2 ng/kg/min subcutaneously (SC) or intravenously (IV) and were optimized to their maximum tolerated dose (MTD) of Remodulin. Subjects were then transitioned to Orenitram XR tablets (oral) based upon their Remodulin dose. Subjects were optimized on Orenitram therapy to a MTD. There were no maximum Remodulin or Orenitram doses specified during the study.

    Drug: Intravenous/Subcutaneous Treprostinil; Oral Treprostinil

Interventions

  • DrugIntravenous/Subcutaneous Treprostinil; Oral Treprostinil

    Drug page: Treprostinil

    Short-term course of IV or SC treprostinil continuous infusion followed by transition to oral treprostinil extended-release (XR) tablets taken 3 times daily (TID)

    Also known as: Remodulin, Orenitram

06

What researchers measure

Primary outcomes

  1. Number of Subjects Achieving Oral Treprostinil Dose

    The number of subjects that achieved an oral treprostinil dose of ≥4 mg TID (or a total daily dose \[TDD\] of 12 mg) at Week 16 (or a dose of ≥0.057 mg/kg TID \[TDD of 0.171 mg/kg\] for subjects \<70 kg).

    Time frame: Assessed at Week 16

Secondary outcomes

  1. Change in 6-minute Walk Distance (6MWD)

    The 6-Minute Walk Test (6MWT) is used to measure exercise ability in patients with chronic respiratory diseases. The distance walked on a predetermined course over 6 minutes was recorded.

    Time frame: From Baseline to Week 16

  2. Change in Borg Dyspnea Score

    The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no shortness of breath) to 10 (worst shortness of breath you have ever had).

    Time frame: From Baseline to Week 16

  3. Number of Subjects With Changes in WHO FC

    WHO FC ranges from I (subjects with PH but without resulting limitation of physical activity) to IV (subjects with PH with inability to carry out any physical activities without symptoms). A lower WHO FC was considered "improved"; a higher WHO FC was considered "worsened."

    Time frame: From Baseline to Week 16

  4. Change in Serum N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels

    NT-proBNP is a hormone produced by the heart. NT-proBNP concentration is associated with changes in right heart morphology and function. The main purpose of NT-proBNP testing is to see if the blood levels of this protein are within the expected range for a healthy person. Normal levels of NT-proBNP are less than 125 pg/mL for people under 75 years old and less than 450 pg/mL for people over age 75. NT-proBNP levels over 900 pg/mL may be a sign of heart failure. The higher the level, the more serious the condition.

    Time frame: From Baseline to Week 16

  5. Change in Echocardiogram Parameters (Change in Cardiac Output)

    ECHOs provide information regarding cardiac structure and function. Cardiac output was summarized at each time point listed.

    Time frame: At Baseline and Week 16

  6. Change in Echocardiogram Parameters (Heart Rate)

    ECHOs provide information regarding cardiac structure and function. Heart rate was summarized at each time point listed.

    Time frame: At Baseline and Week 16

  7. Change in Echocardiogram Parameters (Left Ventricular Outflow Track Dimension)

    ECHOs provide information regarding cardiac structure and function. Left ventricular outflow track (LVOT) dimension was summarized at each time point listed.

    Time frame: At Baseline and Week 16

  8. Change in Echocardiogram Parameters (LVOT Velocity Time Integral)

    ECHOs provide information regarding cardiac structure and function. LVOT velocity time integral was summarized at each time point listed.

    Time frame: At Baseline and Week 16

  9. Change in Echocardiogram Parameters (LV Diameter)

    ECHOs provide information regarding cardiac structure and function. LV diameter was summarized at each time point listed.

    Time frame: At Baseline and Week 16

  10. Change in Echocardiogram Parameters (LV Eccentricity Index [Diastole])

    ECHOs provide information regarding cardiac structure and function. LV Eccentricity Index (Diastole) was summarized at each time point listed. Diastole LV Eccentricity Index is measured during ECHOs to assess how much the shape of the LV deviates from normal while the heart is relaxing (full of blood prior to contraction). A lower Diastole LV Eccentricity Index indicates that the LV is closer to a normal shape during diastole. A higher Diastole LV Eccentricity Index indicates that the LV is more elongated/stretched during diastole, indicating potential heart problems. There is no theoretical minimum or maximum value for the index range.

    Time frame: At Baseline and Week 16

  11. Change in Echocardiogram Parameters (LV Eccentricity Index [Systole])

    ECHOs provide information regarding cardiac structure and function. LV Eccentricity Index (Systole) was summarized at each time point listed. Systole LV Eccentricity Index is measured during ECHOs to assess how much the shape of the LV deviates from normal while the heart is contracting (pumping blood to the body). A lower Systole LV Eccentricity Index indicates that the LV is closer to a normal shape during systole. A higher Systole LV Eccentricity Index indicates that the LV is more elongated/stretched during systole, indicating potential heart problems. There is no theoretical minimum or maximum value for the index range.

    Time frame: At Baseline and Week 16

  12. Change in Echocardiogram Parameters (Pulmonary Valve Acceleration Time)

    ECHOs provide information regarding cardiac structure and function. Pulmonary valve acceleration time was summarized at each time point listed.=.

    Time frame: At Baseline and Week 16

  13. Change in Echocardiogram Parameters (RV/LV Ratio)

    ECHOs provide information regarding cardiac structure and function. RV/LV (diastole) ratio was summarized at each time point listed. RV/LV Ratio is the ratio of right ventricular to left ventricular diameter. A normal RV/LV Ratio is 0.6 to 1.0. When the ratio exceeds 1.0 it is indicative of high pulmonary artery pressure or right ventricular hypertrophy.

    Time frame: At Baseline and Week 16

  14. Change in Echocardiogram Parameters (Right Atrial Area)

    ECHOs provide information regarding cardiac structure and function. Right atrial area was summarized at each time point listed.

    Time frame: At Baseline and Week 16

  15. Change in Echocardiogram Parameters (RV Diameter)

    ECHOs provide information regarding cardiac structure and function. RV diameter was summarized at each time point.

    Time frame: At Baseline and Week 16

  16. Change in Echocardiogram Parameters (RV Free Wall Strain)

    ECHOs provide information regarding cardiac structure and function. RV free wall strain was summarized at each time point listed .

    Time frame: At Baseline and Week 16

  17. Change in Echocardiogram Parameters (RV Myocardial Performance Index)

    ECHOs provide information regarding cardiac structure and function. RV myocardial performance index (MPI) was summarized at each time point listed. RV MPI is a measurement used to assess RV systolic function in patients with PH. MPI correlates with pulmonary arterial pressure. Normal MPI is approximately 0.35. Higher MPI values indicate higher pulmonary arterial pressure.

    Time frame: At Baseline and Week 16

  18. Change in Echocardiogram Parameters (Tricuspid Annular Plane Systolic Excursion)

    ECHOs provide information regarding cardiac structure and function. Tricuspid annular plane systolic excursion was summarized at each time point listed.

    Time frame: At Baseline and Week 16

  19. Change in PAH Symptom Score

    PAH symptoms included fatigue, dyspnea, lower extremity edema, dizziness, syncope, chest pain, and orthopnea. Symptoms were scored (Grades 0 \[none\], 1 \[mild\], 2 \[moderate\], to 3 \[severe\]) except for syncope (0 \[No\], 1 \[Infrequent; 1 episode\], 2 \[Somewhat frequent; 2 to 3 episodes\], and 3 \[Often; \>4 episodes). A lower score was considered "improved"; a higher score was considered "worsened."

    Time frame: At Baseline and Week 16

  20. Change in Patient-reported Outcomes (Health-related Quality of Life)

    The Health-related Quality of Life in Pulmonary Hypertension Questionnaire (emPHasis-10) is a 10-question questionnaire used during clinical assessments that measures quality of life by the patients participating in the study. The patients graded their response to each of the 10 health-related questions on a scale of 0 to 5 based on how they were feeling that day. The most favorable score for each question is 0, and the least favorable score for each question is 5. A total score was then summed for each subject based on their responses to the 10 questions. The lower the total score was (best possible total score was 0), the less living with PH was negatively affecting the quality of the patient's life. The higher the total score (worst possible score was 50), the more living with PH was negatively affecting the quality of the patient's life.

    Time frame: At Baseline and Week 16

  21. Change in Treatment Satisfaction

    The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-question questionnaire that measures the level of satisfaction or dissatisfaction patients have with their study medication in 4 areas: effectiveness (3 questions), side effects (5 questions), convenience (3 questions), and global satisfaction (3 questions). With the exception of the first side effects question (a yes or no question), all items have 5 or 7 responses which are scored from 1 (least satisfied) to 5 or 7 (most satisfied). A total score is then summed for each domain on the following scales: effectiveness 1-21, side effects 1-20, convenience 1-21, and global satisfaction 1-17. Lower total scores in each domain indicate dissatisfaction with the study medication and higher total scores indicate satisfaction.

    Time frame: At Baseline and Week 16

  22. Improvement From Baseline in Clinical Risk Category

    6MWD low risk: \>440 m, intermediate risk: 165-440 m, high risk: \<165 m; NT-proBNP low risk: \<300 ng/L, intermediate risk: 300-1400 ng/L, high risk: \>1400 ng/L; WHO FC: low risk: I or II, intermediate risk: III, high risk: IV; and Right Atrial Area: low risk: \<18 cm², intermediate risk: 18-26 cm², high risk: \>26 cm². Moving from a higher risk category to a low risk category was considered "improved;" moving from a lower risk category to a higher risk category was considered "worsened."

    Time frame: At Baseline and Week 16

  23. Achievement of Low Risk Category in Clinical Parameters

    Low risk categories for the 4 selected parameters were: 6MWD \>440 m, serum NT-proBNP \<300 ng/L, WHO FC I or II, and right atrial area \<18cm². The rows of the table indicate the count of participants that were in the low risk category for the parameter at Week 16.

    Time frame: At Week 16

  24. Overall Achievement

    The percentage of subjects that ended the study in achievement Class 1 (either achieved an Orenitram dose of ≥4 mg TID \[or TDD of 12 mg\] at Week 16 or a dose of ≥0.057 mg/kg TID \[or a TDD of 0.171 mg/kg\] for subjects \<70 kg), Class 2 (achieved a prescribed Orenitram dose ≥2 mg TID and \<4 mg TID \[or a TDD ≥6 mg and \<12 mg\] at specific visit, with at least 2 of the following 3 clinical parameters: 6MWD increase by ≥10% or ≥30 m from baseline, serum NT-proBNP reduction \>30% from baseline, or WHO FC I or II), or Class 3 (were not Class 1 or Class 2, or with class undetermined).

    Time frame: At Week 16

  25. Transition and Maintenance of Orenitram Therapy

    The percentage of subjects that transitioned to oral treprostinil at any dose and were maintained on therapy at Week 16 (considered a "successful" result).

    Time frame: At Week 16

07

Results

Posted Aug 7, 2023

Participant flow

Participant flow — Overall Study
MilestoneIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Started35
Completed28
Not completed7
Withdrew: Adverse event2
Withdrew: Death1
Withdrew: Physician decision1
Withdrew: Withdrawal by subject1
Withdrew: Protocol violation2

Outcome measures

PrimaryNumber of Subjects Achieving Oral Treprostinil Dose

The number of subjects that achieved an oral treprostinil dose of ≥4 mg TID (or a total daily dose \[TDD\] of 12 mg) at Week 16 (or a dose of ≥0.057 mg/kg TID \[TDD of 0.171 mg/kg\] for subjects \<70 kg).

Time frame:
Assessed at Week 16
Reported as:
Count of participants · Participants
Number of Subjects Achieving Oral Treprostinil Dose
ParticipantsIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Number of Subjects Achieving Oral Treprostinil Dose23
SecondaryChange in 6-minute Walk Distance (6MWD)

The 6-Minute Walk Test (6MWT) is used to measure exercise ability in patients with chronic respiratory diseases. The distance walked on a predetermined course over 6 minutes was recorded.

Time frame:
From Baseline to Week 16
Reported as:
Median · meters
Change in 6-minute Walk Distance (6MWD)
metersIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in 6-minute Walk Distance (6MWD)25.00 (-210.0 to 112.0)
SecondaryChange in Borg Dyspnea Score

The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6MWT. Scores range from 0 (no shortness of breath) to 10 (worst shortness of breath you have ever had).

Time frame:
From Baseline to Week 16
Reported as:
Median · score on a scale
Change in Borg Dyspnea Score
score on a scaleIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Borg Dyspnea Score-1.00 (-5.0 to 4.0)
SecondaryNumber of Subjects With Changes in WHO FC

WHO FC ranges from I (subjects with PH but without resulting limitation of physical activity) to IV (subjects with PH with inability to carry out any physical activities without symptoms). A lower WHO FC was considered "improved"; a higher WHO FC was considered "worsened."

Time frame:
From Baseline to Week 16
Reported as:
Count of participants · Participants
Number of Subjects With Changes in WHO FC
ParticipantsIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Improved19
Worsened1
No Change8
SecondaryChange in Serum N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels

NT-proBNP is a hormone produced by the heart. NT-proBNP concentration is associated with changes in right heart morphology and function. The main purpose of NT-proBNP testing is to see if the blood levels of this protein are within the expected range for a healthy person. Normal levels of NT-proBNP are less than 125 pg/mL for people under 75 years old and less than 450 pg/mL for people over age 75. NT-proBNP levels over 900 pg/mL may be a sign of heart failure. The higher the level, the more serious the condition.

Time frame:
From Baseline to Week 16
Reported as:
Median · ng/L
Change in Serum N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels
ng/LIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Serum N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Levels-134.0 (-3896 to 556)
SecondaryChange in Echocardiogram Parameters (Change in Cardiac Output)

ECHOs provide information regarding cardiac structure and function. Cardiac output was summarized at each time point listed.

Time frame:
At Baseline and Week 16
Reported as:
Median · L/min
Change in Echocardiogram Parameters (Change in Cardiac Output)
L/minIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (Change in Cardiac Output)0.55 (-1.7 to 3.1)
SecondaryChange in Echocardiogram Parameters (Heart Rate)

ECHOs provide information regarding cardiac structure and function. Heart rate was summarized at each time point listed.

Time frame:
At Baseline and Week 16
Reported as:
Median · beats/min
Change in Echocardiogram Parameters (Heart Rate)
beats/minIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (Heart Rate)1.50 (-17.0 to 23.0)
SecondaryChange in Echocardiogram Parameters (Left Ventricular Outflow Track Dimension)

ECHOs provide information regarding cardiac structure and function. Left ventricular outflow track (LVOT) dimension was summarized at each time point listed.

Time frame:
At Baseline and Week 16
Reported as:
Median · mm
Change in Echocardiogram Parameters (Left Ventricular Outflow Track Dimension)
mmIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (Left Ventricular Outflow Track Dimension)0.42 (-1.1 to 2.6)
SecondaryChange in Echocardiogram Parameters (LVOT Velocity Time Integral)

ECHOs provide information regarding cardiac structure and function. LVOT velocity time integral was summarized at each time point listed.

Time frame:
At Baseline and Week 16
Reported as:
Median · cm
Change in Echocardiogram Parameters (LVOT Velocity Time Integral)
cmIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (LVOT Velocity Time Integral)0.93 (-6.8 to 7.7)
SecondaryChange in Echocardiogram Parameters (LV Diameter)

ECHOs provide information regarding cardiac structure and function. LV diameter was summarized at each time point listed.

Time frame:
At Baseline and Week 16
Reported as:
Median · mm
Change in Echocardiogram Parameters (LV Diameter)
mmIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (LV Diameter)3.52 (-4.4 to 14.1)
SecondaryChange in Echocardiogram Parameters (LV Eccentricity Index [Diastole])

ECHOs provide information regarding cardiac structure and function. LV Eccentricity Index (Diastole) was summarized at each time point listed. Diastole LV Eccentricity Index is measured during ECHOs to assess how much the shape of the LV deviates from normal while the heart is relaxing (full of blood prior to contraction). A lower Diastole LV Eccentricity Index indicates that the LV is closer to a normal shape during diastole. A higher Diastole LV Eccentricity Index indicates that the LV is more elongated/stretched during diastole, indicating potential heart problems. There is no theoretical minimum or maximum value for the index range.

Time frame:
At Baseline and Week 16
Reported as:
Median · Eccentricity Index
Change in Echocardiogram Parameters (LV Eccentricity Index [Diastole])
Eccentricity IndexIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (LV Eccentricity Index [Diastole])0.04 (-0.3 to 0.3)
SecondaryChange in Echocardiogram Parameters (LV Eccentricity Index [Systole])

ECHOs provide information regarding cardiac structure and function. LV Eccentricity Index (Systole) was summarized at each time point listed. Systole LV Eccentricity Index is measured during ECHOs to assess how much the shape of the LV deviates from normal while the heart is contracting (pumping blood to the body). A lower Systole LV Eccentricity Index indicates that the LV is closer to a normal shape during systole. A higher Systole LV Eccentricity Index indicates that the LV is more elongated/stretched during systole, indicating potential heart problems. There is no theoretical minimum or maximum value for the index range.

Time frame:
At Baseline and Week 16
Reported as:
Median · Eccentricity Index
Change in Echocardiogram Parameters (LV Eccentricity Index [Systole])
Eccentricity IndexIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (LV Eccentricity Index [Systole])0.09 (-1.0 to 0.7)
SecondaryChange in Echocardiogram Parameters (Pulmonary Valve Acceleration Time)

ECHOs provide information regarding cardiac structure and function. Pulmonary valve acceleration time was summarized at each time point listed.=.

Time frame:
At Baseline and Week 16
Reported as:
Median · msec
Change in Echocardiogram Parameters (Pulmonary Valve Acceleration Time)
msecIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (Pulmonary Valve Acceleration Time)4.43 (-22.0 to 41.2)
SecondaryChange in Echocardiogram Parameters (RV/LV Ratio)

ECHOs provide information regarding cardiac structure and function. RV/LV (diastole) ratio was summarized at each time point listed. RV/LV Ratio is the ratio of right ventricular to left ventricular diameter. A normal RV/LV Ratio is 0.6 to 1.0. When the ratio exceeds 1.0 it is indicative of high pulmonary artery pressure or right ventricular hypertrophy.

Time frame:
At Baseline and Week 16
Reported as:
Median · Ratio
Change in Echocardiogram Parameters (RV/LV Ratio)
RatioIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (RV/LV Ratio)-0.6 (-0.6 to 0.3)
SecondaryChange in Echocardiogram Parameters (Right Atrial Area)

ECHOs provide information regarding cardiac structure and function. Right atrial area was summarized at each time point listed.

Time frame:
At Baseline and Week 16
Reported as:
Median · cm^2
Change in Echocardiogram Parameters (Right Atrial Area)
cm^2Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (Right Atrial Area)-2.88 (-15.8 to 5.3)
SecondaryChange in Echocardiogram Parameters (RV Diameter)

ECHOs provide information regarding cardiac structure and function. RV diameter was summarized at each time point.

Time frame:
At Baseline and Week 16
Reported as:
Median · mm
Change in Echocardiogram Parameters (RV Diameter)
mmIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (RV Diameter)-2.61 (-16.6 to 18.8)
SecondaryChange in Echocardiogram Parameters (RV Free Wall Strain)

ECHOs provide information regarding cardiac structure and function. RV free wall strain was summarized at each time point listed .

Time frame:
At Baseline and Week 16
Reported as:
Median · percent
Change in Echocardiogram Parameters (RV Free Wall Strain)
percentIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (RV Free Wall Strain)1.28 (-8.2 to 15.4)
SecondaryChange in Echocardiogram Parameters (RV Myocardial Performance Index)

ECHOs provide information regarding cardiac structure and function. RV myocardial performance index (MPI) was summarized at each time point listed. RV MPI is a measurement used to assess RV systolic function in patients with PH. MPI correlates with pulmonary arterial pressure. Normal MPI is approximately 0.35. Higher MPI values indicate higher pulmonary arterial pressure.

Time frame:
At Baseline and Week 16
Reported as:
Median · MPI
Change in Echocardiogram Parameters (RV Myocardial Performance Index)
MPIIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (RV Myocardial Performance Index)-0.08 (-0.6 to 0.5)
SecondaryChange in Echocardiogram Parameters (Tricuspid Annular Plane Systolic Excursion)

ECHOs provide information regarding cardiac structure and function. Tricuspid annular plane systolic excursion was summarized at each time point listed.

Time frame:
At Baseline and Week 16
Reported as:
Median · mm
Change in Echocardiogram Parameters (Tricuspid Annular Plane Systolic Excursion)
mmIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Echocardiogram Parameters (Tricuspid Annular Plane Systolic Excursion)1.20 (-5.0 to 7.8)
SecondaryChange in PAH Symptom Score

PAH symptoms included fatigue, dyspnea, lower extremity edema, dizziness, syncope, chest pain, and orthopnea. Symptoms were scored (Grades 0 \[none\], 1 \[mild\], 2 \[moderate\], to 3 \[severe\]) except for syncope (0 \[No\], 1 \[Infrequent; 1 episode\], 2 \[Somewhat frequent; 2 to 3 episodes\], and 3 \[Often; \>4 episodes). A lower score was considered "improved"; a higher score was considered "worsened."

Time frame:
At Baseline and Week 16
Reported as:
Count of participants · Participants
Change in PAH Symptom Score
ParticipantsIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Fatigue — Improved11
Fatigue — Worsened3
Fatigue — No Change14
Dyspnea — Improved17
Dyspnea — Worsened1
Dyspnea — No Change10
Lower Extremity Edema — Improved8
Lower Extremity Edema — Worsened4
Lower Extremity Edema — No Change16
Dizziness — Improved7
Dizziness — Worsened4
Dizziness — No Change17
Syncope — Improved1
Syncope — Worsened1
Syncope — No Change26
Chest Pain — Improved3
Chest Pain — Worsened2
Chest Pain — No Change23
Orthopnea — Improved8
Orthopnea — Worsened2
Orthopnea — No Change18
SecondaryChange in Patient-reported Outcomes (Health-related Quality of Life)

The Health-related Quality of Life in Pulmonary Hypertension Questionnaire (emPHasis-10) is a 10-question questionnaire used during clinical assessments that measures quality of life by the patients participating in the study. The patients graded their response to each of the 10 health-related questions on a scale of 0 to 5 based on how they were feeling that day. The most favorable score for each question is 0, and the least favorable score for each question is 5. A total score was then summed for each subject based on their responses to the 10 questions. The lower the total score was (best possible total score was 0), the less living with PH was negatively affecting the quality of the patient's life. The higher the total score (worst possible score was 50), the more living with PH was negatively affecting the quality of the patient's life.

Time frame:
At Baseline and Week 16
Reported as:
Median · score on a scale
Change in Patient-reported Outcomes (Health-related Quality of Life)
score on a scaleIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Change in Patient-reported Outcomes (Health-related Quality of Life)-3.0 (-33 to 16)
SecondaryChange in Treatment Satisfaction

The Treatment Satisfaction Questionnaire for Medication (TSQM) is a 14-question questionnaire that measures the level of satisfaction or dissatisfaction patients have with their study medication in 4 areas: effectiveness (3 questions), side effects (5 questions), convenience (3 questions), and global satisfaction (3 questions). With the exception of the first side effects question (a yes or no question), all items have 5 or 7 responses which are scored from 1 (least satisfied) to 5 or 7 (most satisfied). A total score is then summed for each domain on the following scales: effectiveness 1-21, side effects 1-20, convenience 1-21, and global satisfaction 1-17. Lower total scores in each domain indicate dissatisfaction with the study medication and higher total scores indicate satisfaction.

Time frame:
At Baseline and Week 16
Reported as:
Median · score on a scale
Change in Treatment Satisfaction
score on a scaleIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Effectiveness4.76 (-28.6 to 42.9)
Side Effects5.00 (-50.0 to 35.0)
Convenience-4.76 (-52.4 to 28.6)
Global Satisfaction0.00 (-47.1 to 35.3)
SecondaryImprovement From Baseline in Clinical Risk Category

6MWD low risk: \>440 m, intermediate risk: 165-440 m, high risk: \<165 m; NT-proBNP low risk: \<300 ng/L, intermediate risk: 300-1400 ng/L, high risk: \>1400 ng/L; WHO FC: low risk: I or II, intermediate risk: III, high risk: IV; and Right Atrial Area: low risk: \<18 cm², intermediate risk: 18-26 cm², high risk: \>26 cm². Moving from a higher risk category to a low risk category was considered "improved;" moving from a lower risk category to a higher risk category was considered "worsened."

Time frame:
At Baseline and Week 16
Reported as:
Count of participants · Participants
Improvement From Baseline in Clinical Risk Category
ParticipantsIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
6MWD — Improved4
6MWD — Worsened1
6MWD — No Change22
NT-proBNP — Improved11
NT-proBNP — Worsened1
NT-proBNP — No Change16
WHO FC — Improved11
WHO FC — Worsened1
WHO FC — No Change16
Right Atrial Area — Improved8
Right Atrial Area — Worsened1
Right Atrial Area — No Change14
SecondaryAchievement of Low Risk Category in Clinical Parameters

Low risk categories for the 4 selected parameters were: 6MWD \>440 m, serum NT-proBNP \<300 ng/L, WHO FC I or II, and right atrial area \<18cm². The rows of the table indicate the count of participants that were in the low risk category for the parameter at Week 16.

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Achievement of Low Risk Category in Clinical Parameters
ParticipantsIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
6MWD10
NT-proBNP19
WHO FC24
Right Atrial Area14
SecondaryOverall Achievement

The percentage of subjects that ended the study in achievement Class 1 (either achieved an Orenitram dose of ≥4 mg TID \[or TDD of 12 mg\] at Week 16 or a dose of ≥0.057 mg/kg TID \[or a TDD of 0.171 mg/kg\] for subjects \<70 kg), Class 2 (achieved a prescribed Orenitram dose ≥2 mg TID and \<4 mg TID \[or a TDD ≥6 mg and \<12 mg\] at specific visit, with at least 2 of the following 3 clinical parameters: 6MWD increase by ≥10% or ≥30 m from baseline, serum NT-proBNP reduction \>30% from baseline, or WHO FC I or II), or Class 3 (were not Class 1 or Class 2, or with class undetermined).

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Overall Achievement
ParticipantsIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Class 123
Class 22
Class 34
SecondaryTransition and Maintenance of Orenitram Therapy

The percentage of subjects that transitioned to oral treprostinil at any dose and were maintained on therapy at Week 16 (considered a "successful" result).

Time frame:
At Week 16
Reported as:
Count of participants · Participants
Transition and Maintenance of Orenitram Therapy
ParticipantsIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Transition and Maintenance of Orenitram Therapy28

Adverse events

Collected over Adverse events (AEs) were captured from when the subject signed the informed consent form until the subject completed the study or was withdrawn from the study, up to 20 weeks.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Intravenous/Subcutaneous Treprostinil; Oral Treprostinil1/35 (2.9%)10/35 (28.6%)35/35 (100%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
Device dislocationProduct Issues2/35
Acute respiratory failureRespiratory, thoracic and mediastinal disorders1/35
DyspnoeaRespiratory, thoracic and mediastinal disorders1/35
Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders1/35
Respiratory failureRespiratory, thoracic and mediastinal disorders1/35
Febrile neutropeniaBlood and lymphatic system disorders1/35
Right ventricular failureCardiac disorders1/35
Upper gastrointestinal haemorrhageGastrointestinal disorders1/35
Bacterial sepsisInfections and infestations1/35
EndocarditisInfections and infestations1/35
Most frequent other events
Showing 10 of 41
Most frequent other events
EventIntravenous/Subcutaneous Treprostinil; Oral Treprostinil
HeadacheNervous system disorders30/35
NauseaGastrointestinal disorders25/35
DiarrhoeaGastrointestinal disorders21/35
FlushingVascular disorders20/35
Pain in jawMusculoskeletal and connective tissue disorders18/35
VomitingGastrointestinal disorders15/35
Pain in extremityMusculoskeletal and connective tissue disorders15/35
FatigueGeneral disorders14/35
Infusion site painGeneral disorders9/35
PainGeneral disorders9/35

Baseline characteristics

Age, Continuous
Age, Continuous(years)Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Median56.0 (35 to 72)
Sex: Female, Male
Sex: Female, Male(Participants)Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Female24
Male11
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Hispanic or Latino3
Not Hispanic or Latino32
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
American Indian or Alaska Native1
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American4
White29
More than one race0
Unknown or Not Reported1
PAH Etiology
PAH Etiology(Participants)Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Idiopathic PAH15
Associated with connective tissue disease9
Associated with appetite suppressant or toxin use7
Associated with HIV infection1
Heritable PAH1
Other2
Associated with repaired congenital systemic-to-pulmonary shunts0
Days Since Initial PAH Diagnosis
Days Since Initial PAH Diagnosis(days)Intravenous/Subcutaneous Treprostinil; Oral Treprostinil
Median245.0 (7 to 1959)
08

Study locations

11 sites
  • University of California San Francisco - Fresno
    Fresno, California 93701, United States
  • Harbor-UCLA Medical Center
    Torrance, California 90502, United States
  • Florida Hospital
    Orlando, Florida 32803, United States
  • Piedmont Healthcare Pulmonary and Critical Care Research
    Austell, Georgia 30106, United States
  • St. Vincent Medical Group
    Indianapolis, Indiana 46260, United States
  • University of Nebraska Medical Center
    Omaha, Nebraska 68198, United States
  • University of New Mexico Health Sciences Center
    Albuquerque, New Mexico 87131, United States
  • University of Cincinnati Health
    Cincinnati, Ohio 45267, United States
  • The Ohio State University Wexner Medical Center
    Columbus, Ohio 43210, United States
  • Integris Baptist Medical Center
    Oklahoma City, Oklahoma 73112, United States
  • UPMC Presbytarian Hospital
    Pittsburgh, Pennsylvania 15213, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2019 to primary completion in May 2022, 39 months.

Results were first posted in Aug 2023, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 20, 2018
First posted
Apr 13, 2018
StartActual
Jan 31, 2019
Primary completionActual
May 11, 2022
CompletionActual
May 11, 2022
Results first posted
Aug 7, 2023
Last update
Aug 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03497689
Responsible party
Sponsor
First posted
Apr 13, 2018
Start date
Jan 31, 2019
Primary completion
May 11, 2022
Completion
May 11, 2022
Results posted
Aug 7, 2023
Last update
Aug 7, 2023

Study contacts

Chad E Miller, MD
principal investigator · Piedmont Healthcare Pulmonary and Critical Care Research

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion